The effect of ibustrin on early aortocoronary bypass patency.
Results of a randomized study designed to compare the effect of ASA and dipyridamole with that of Ibustrin on early patency of low-flow aortocoronary bypasses are presented. The study included 49 patients in whom at least one of the bypasses showed an intraoperative blood flow rate of 40 ml/min or less, i.e., reconstructions at highest risk of early thrombosis. Of 39 bypasses in the ASA and dipyridamole group, 11 (28.2%) were occluded and, in the Ibustrin group, eight (25.8%) out of 31 bypasses were found to be occluded on the angiogram performed 7-10 days postoperatively. There is no statistically significant difference in the patency rate between these two groups. Administration of Ibustrin was not associated with any side effects, and leads to the same improvement of early ACB patency as administration of ASA and dipyridamole.